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Background: The production, prescription, and consumption of opioid analgesics to treat non-cancer pain have
increased dramatically in the USA in the past decade. As a result, misuse of these opioids has increased; overdose
and transition to riskier forms of drug use have also emerged. Research points to a trend in transition to drug
injection among those misusing prescription opioids, where clusters of acute hepatitis C virus (HCV) infection are
now being reported. This systematic review and meta-analysis aims to synthesize the prevalence of prescription
opioid misuse in the USA and examine the rate of transition to injection drug use and incident HCV in these new
people who inject drugs (PWID).
Methods/design: Eligible studies will include quantitative, empirical data including national survey data. Scientific
databases will be searched using a comprehensive search strategy; proceedings of scientific conferences, reference lists,
and personal communications will also be searched. Quality ratings will be assigned to each eligible report using the
Newcastle-Ottawa Scale. Pooled estimates of incidence rates and measures of association will be calculated using random
effects models. Heterogeneity will be assessed at each stage of data synthesis.
Discussion: A unique typology of drug use is emerging which is characterized by antecedent prescription opioid misuse
among PWID. As the epidemic of prescription opioid misuse matures, this will likely serve as a persistent source of new
PWID. Persons who report a recent transition to drug injection are characterized by high rates of HCV seroincidence of 40
per 100 person years or higher. Given the potential for the persistence and escalation of the consequences of prescription
opioid misuse in the USA, there is a critical need for synthesis of the current state of the epidemic in order to inform
future public health interventions and policy.
Systematic review registration: PROSPERO CRD42014008870.
Keywords: Prescription opioid misuse, Initiation of injection drug use, Epidemiology, Hepatitis C, Systematic reviewBackground
The production, prescription, and consumption of pre-
scription opioids—specifically pharmaceutical opioid anal-
gesics designed and used for the treatment of severe or
chronic non-cancer pain—have increased rapidly over the
past decade [1-3]. Since 1999, the number of prescriptions* Correspondence: ae.jordan@nyu.edu
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unless otherwise stated.for opioid analgesics rose by 350% in the USA [4]. The
upsurge in the availability and use of prescription opioids
has been linked to their widespread misuse [5]. High rates
of misuse have been reported in parts of Europe, Australia,
and North America; recent data shows that prevalence of
prescription opioid misuse has also emerged, and is rising,
in parts of Asia and Africa [6]. Although Americans consti-
tute only 4.6% of the world's population, they consume
80% of the global opioid supply [7,8]. As of 2012, prescrip-
tion opioids surpassed marijuana as the most misusedLtd. This is an Open Access article distributed under the terms of the Creative
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has recently been classified as an epidemic [9].
The rapid rise of prescription opioid misuse in the USA
has been most dramatic among young people [10-12]. The
incidence rate of prescription opioid misuse for 12–25-year
olds was relatively stable and low from 1979 through the
early 1990s; incidence began to rise in 1994 from 12–13
per 1,000 persons to 30–50 per 1,000 in 2001 among those
12–25-year olds [13,14]. In 2010, 11%, or 3.4 million, 18-
to 25-year olds were reporting prescription opioid misuse
[15-17]. A recent US survey of suburban adolescents and
early adults showed that one-third reported misuse of pre-
scription opioids by the age of 21 [16].
There is significant morbidity and mortality associated
with the misuse of prescription opioids, including unin-
tentional overdose. Overdose deaths due to prescription
opioids quadrupled between 1999 and 2007 [18]. In 2008,
overdose deaths due to misuse of prescription opioids
ranged from 5.5–27 per 100,000 persons depending on
geographic location [19]. Overdose due to prescription
opioids now exceeds those due to heroin and cocaine
combined [20]. Emergency departments have also seen a
dramatic rise in visits related to prescription opioid use
where visits have more than doubled to nearly half a mil-
lion since 2004 [21,22]. Annual direct health care costs
due to prescription opioid misuse have been estimated to
be $55.7 billion [23].
A less well-documented phenomenon has been the
pathway from prescription opioid misuse to injection of
both synthetic opioids and heroin [13]. Both qualitative
and survey data point to a trend of antecedent prescrip-
tion opioid misuse among new people who inject drugs
(PWID) [24-26]. As drug dependence and tolerance in-
crease, many—perhaps 10%–20%—who are misusing
these prescription drugs will escalate to injection [27,28].
In a study by Mars et al., young adult heroin users were
more likely to have misused prescription opioids prior to
transitioning to heroin injection at rates much higher
than their older counterparts [13].
It is among these new PWID that clusters of hepatitis C
(HCV) infection have been observed [3,29]. As the epi-
demic of misuse of prescription opioids matures, it will
likely serve as a persistent source of new PWID, a group
characterized by high rates of HCV seroconversion of 40
per 100 person years or higher [30,31]. Given the high and
sustained availability of prescription opioids via illicit and
prescription drug markets, and the risk of transition to drug
injection among those using prescription opioids, outbreaks
of acute HCV are likely to continue. The threat of emergent
and persistent HCV infection among this growing risk
population could cause an escalation in national prevalence
and incidence. The purpose of this review is to synthesize
the research reporting on the consequences of the recent
upsurge in the misuse of prescription opioids in the USA.Methods/design
Design and scope
This study will consist of a systematic review and meta-
analysis of the prevalence of prescription opioid misuse,
rates of transition from prescription opioid misuse to
first-time injection drug use and the incidence of HCV
among these new PWID. This review will characterize
the prevalence of prescription opioid misuse in US set-
tings from both non-probability and survey data and cal-
culate pooled and subgroup-specific rates of transition
to drug injection, and calculate pooled and subgroup-
specific HCV incidence rates in those who initiate drug
injection using random effects meta-regression models.
Criteria for considering studies
Inclusion and exclusion criteria
Published and unpublished data reports, personal com-
munications, dissertations, abstracts, conference presen-
tations, and book chapters are eligible for inclusion in
the study. Data reports will be included if they became
available from 1 January 1990 through 30 June 2014.
Studies will be included if they reported on prevalence
or incidence of prescription opioid misuse or rates of
transition from prescription opioid misuse to first-time
injection drug use and HCV incidence among those re-
cently transitioned. Data reports where recent initiates
of drug injection are a subset, and not the main focus of
study, will be eligible for inclusion in the review. Confer-
ence abstracts will be included if sufficient data were re-
ported. Case reports or case series where the total number
of cases was fewer than 10 will be excluded. Case-control,
cohort, and cross-sectional study designs will be eligible for
inclusion in the systematic review. Studies not eligible for
inclusion include randomized controlled trials of interven-
tions intended to alter the outcomes studied in this review.
Outcome measures
There are three main outcomes of this systematic review:
prescription opioid misuse prevalence and incidence, rates
of transition to drug injection among prescription opioid
misusers, and HCV seroconversion among new PWID
with antecedent prescription opioid misuse. Definitions of
what constitutes a newly transitioned PWID used in the
data reports will be recorded; higher quality ratings will be
given to reports that confirm drug injection naivety among
those defined as being new PWID and that provide a time
frame for when initiation into injection drug use occurred.
Rates of acute HCV infection or seroconversion will be
included. We define subjects with ‘HCV seroconversion’ or
‘acute HCV’ as those who have been screened and tested
positive for HCV antibody (serology) or RNA within
12 months of previously testing negative. We adopted the
European AIDS Treatment Network (European NEAT)
Acute Hepatitis C Infection Consensus Panel criteria [32]:
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RNA and a documented negative HCV RNA or nega-
tive HCV antibody in the previous 12 months.
Alternative criteria - includes positive HCV RNA and
an elevated ALT with or without other clinical signs of
hepatitis.
Data reports using the preferred criteria will be given
higher quality ratings than those that use the alternative
criteria. An initial examination of the available literature
suggested that there would be very few reports of HCV
infection determined by laboratory testing. Thus, we will
include studies that rely on self-reported HCV status but
they will receive lower quality scores and be subject to
greater scrutiny in analysis and interpretation.
Exposure measures
The primary exposure of interest to this systematic re-
view is prescription opioid misuse. In response to the
use of varied and idiosyncratic definitions and measure-
ments of prescription opioid misuse in the literature,
there has been a collective effort toward the adoption of
a standardized operational definition of misuse. In 2006,
the National Institute of Drug Abuse (NIDA) officially de-
fined prescription opioid ‘abuse’ as follows: ‘[opioid abuse
includes any] intentional use of opioids outside of a physi-
cian's prescription for a bona fide medical condition, ex-
cluding accidental misuse’ [1]. The systematic review will
record the operational definitions of misuse used in the
studies (e.g., any nonmedical use of a PO; any use of a PO;
taking a PO for the way it makes one feel). We anticipate
that the ‘dose’ of PO exposure in terms of frequency, re-
cency, and amount will be related to the likelihood of
transitioning to injection drug use; this will be examined
in the analysis. For example, the rate of transition to injec-
tion would be compared between studies defining PO
misuse as any nonmedical use in the participant's lifetime
(‘low’ exposure dose) and studies that report daily PO mis-
use during a recent period (‘high’ dose).
Search strategy
A medical librarian was consulted regarding the search
methods. Automated searches of published literature (title,
abstract, and keywords) will be conducted using the follo-
wing electronic databases: PubMed, OVID, EMBASE, Web
of Knowledge, and PsycINFO. Search terms included those
related to prescription opioid misuse, initiation of injection
drug use, and HCV incidence among new PWID.
Screening and data collection
As an initial screening step, the title and abstract of data
reports retrieved via the search will be read by the
study's Principal Investigator (PI; HH) and the Project
Director (PD; AEJ); abstracts with any mention of themain outcomes of interest will be considered for inclu-
sion and the full text article will be retrieved. A pilot
study will be carried out to test and refine procedures
for screening and data abstraction. Discrepancies be-
tween the pilot screening results will be discussed and
the protocol will be revised to clarify procedures. This
process will be repeated until consensus is reached.
Abstracts and full-text articles obtained via the search
strategy will be imported into Endnote X6 (Reuters) and
duplicates will be deleted. Reasons for exclusion will be
recorded. Relevant data will be abstracted onto a paper
instrument adapted from those used in a series of prior
systematic reviews led by the PI. Once this is complete,
data will be entered into a Microsoft Access database.
Data to be abstracted will include: citation information;
study years and locations; study design; methods and
sites used to recruit study participants; prevalence and
incidence of prescription drug misuse, and factors asso-
ciated with both measures; rates of transition to injec-
tion drug use and factors associated with transition;
HCV seroincidence among new PWID reporting previ-
ous prescription opioid misuse; factors associated with
HCV seroconversion; and other relevant demographic
characteristics of the study sample.Quality assurance
The PD and a Master's-level trained epidemiologist, both
with expertise in research methodology, HCV, drug use,
and systematic reviews and meta-analytic methods, and
a research assistant with expertise in research methods
and training on HCV and drug use, will carry out cod-
ing; the PD will review all coding forms to ensure com-
pleteness and accuracy of coding. During weekly staff
meetings, any inconsistencies will be discussed and re-
solved. A written study manual was developed to guide
the process and to record special cases and their
resolution.Study quality and critical appraisal
In order to assess the quality of data reports, this synthe-
sis will employ a quality rating procedure based on the
Newcastle-Ottawa Scale (NOS) which assigns quality
ratings to studies in relation to threats to internal valid-
ity (selection bias, misclassification of exposure or out-
come, and confounding due to non-comparability of the
groups being compared) [33]. Some types of bias will be
addressed through screening of reports for eligibility. Eli-
gibility screening also will address potential misclassifi-
cation of the outcome (e.g., acute or recent vs. chronic
HCV infection). In addition to the NOS ratings, publica-
tion bias will be examined by comparing estimates be-
tween published and unpublished studies and by the use
of funnel plots [34].
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Selection bias has the potential to affect both case-control
and cohort studies; the evaluation of selection bias in this
synthesis will require the assessment of whether similar
and adequate methods were employed to classify those
who constituted cases and controls. In case-control studies,
we will assess whether cases and controls arose from the
same underlying population. Selection bias will be assessed
in cohort studies in relation to whether the selection of the
exposed cohort was related to the likelihood of any of the
outcomes of interest (e.g., prescription opioid misuse).
Comparability
Quality assessment will also examine the comparability of
cases to controls in case-control studies. In these studies,
we will examine the use of matching or adjustment for con-
founding based on the differential distribution of factors
among cases and controls in order to reduce biases. In co-
hort studies, we will assess whether the study adjusted for
important differences across the exposed and unexposed
cohorts. Adjusting for these differences is a critical factor in
assessing the quality of the study's reporting of an associ-
ation between assessing the exposure and the outcome.
Misclassification
Higher quality ratings will be given to data reports that
provide an explicit definition of exposure and outcome. In
case-control studies, classification of cases and controls
with respect to exposure must be unbiased, and use of the
same method of ascertaining exposure for cases and con-
trols is preferred. In cohort studies, misclassification of
outcome will be assessed in the quality ratings; for ex-
ample, studies using the NEAT preferred definition of
acute or recent HCV infection will be given higher scores.
Data analysis
Aggregate (study-level) data will be used in this synthe-
sis. Synthesis begins with the search for homogeneous
subsets within sets of studies, followed by meta-analysis
and calculation of summary estimates within the homo-
geneous subsets. Graphical and statistical analysis will be
conducted using software designed specifically for meta-
analysis. Variability in effects among the studies may reflect
important differences, or confounding by other factors.
Therefore, evidence of heterogeneity will be evaluated at
each step in the analysis to distinguish between true vari-
ation of effects and heterogeneity due to other differences.
Data reports that present on HCV seroincidence among
new PWID but did not inquire about previous experience
injecting drugs (i.e., confirming that all new PWID were
naïve to injection as a form of drug administration) will be
analyzed separately. The reason for this is that we believe
new PWID present unique risk factors for HCV acquisi-
tion [35-37].Reports will also be analyzed by year of data collection
and/or year of publication in order to examine whether
there are changes in exposures or outcomes as the epi-
demic matures and as new policies are adopted.
Effect measures reported as hazard ratios, risk ratios, or
relative risks will be transformed into odds ratios using
standard methods. Meta-analysis and random effects meta-
regression will be carried out. Meta-regression will be con-
ducted to identify factors associated with variation in effect
sizes (e.g., with higher versus lower effect sizes).Discussion
Pharmaceutical opioid misuse has been a long-standing
public health problem in the USA [7,38,39]. However,
overall misuse rates have historically been stable and
relatively low-level in scope [13,38].
We anticipate that the majority of data reports retrieved
will present prescription opioid misuse prevalence data
from both non-probability samples (e.g., cohort studies)
and household-based surveys (e.g., National Survey on
Drug Use and Health). A casual examination of the litera-
ture also suggests that there are a substantial number of
qualitative research studies on the topic that will not be
eligible, but may provide important insights into the inter-
pretation of the quantitative results.
Since the early 1990s, the annual number of prescrip-
tions dispensed for opioid analgesics to treat non-cancer
pain tripled reaching into the hundreds of millions and
are now the most prescribed class of medications in the
USA [40]. The average milligram prescribed per person
rose from 74 to 369 between 1997 and 2007, an increase
of over 400 percent [41]. Morbidity and mortality due to
prescription opioid use in the form of accidental over-
dose and transition to riskier forms of drug use, rose
dramatically in tandem. Given the potential for the per-
sistence and escalation of the morbidity and mortality of
prescription opioid misuse in the USA, there is a critic-
ally important role for a systematic review of this kind
to inform future interventions and policy on this public
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